AMT Medical

What AMT Medical does

AMT Medical B.V. is a Dutch clinical-stage medical device company founded in 2017 and headquartered in Utrecht (with manufacturing operations in Ede), developing the ELANA® Anastomotic System, a sutureless clip-and-laser platform designed to create the distal anastomosis in coronary artery bypass grafting (CABG). The system combines a specially designed titanium clip that mechanically connects a graft vessel to the coronary artery with an excimer-laser catheter that creates the arteriotomy, eliminating the need for manual suturing. The underlying technology was originally developed for neurosurgery (used in hundreds of aneurysm patients) and has been redesigned and optimized by AMT Medical for cardiac application, supporting both open and minimally invasive approaches including off-pump beating-heart surgery, MIDCAB, and, in the company's stated roadmap, robotic-assisted TECAB. The product is positioned to standardize anastomoses that today depend heavily on individual surgeon skill, potentially expanding adoption of less invasive CABG.

The company is pre-revenue and does not yet hold CE marking or FDA approval. It is currently executing the SAFE-CAB trial program: Phase I (first ten patients, results presented at the 36th EACTS Annual Meeting in Milan in October 2022) is complete, and Phase II (75 enrolled patients, started September 2023) is underway to support CE marking in Europe. AMT Medical is in parallel in final discussions with the US FDA to begin an Early Feasibility Trial. The company has obtained EN ISO 13485:2016 certification (May 2023), operates an ISO 7 cleanroom at the Zonneoord campus in Ede for component production, and collaborates with leading clinical centers including St. Antonius Hospital Nieuwegein, UMC Utrecht, and Deutsches Herzzentrum Berlin (Charité). The business model is single-use hardware sales of the ELANA Clip and laser catheter system to hospitals and cardiac surgery centers; pricing is not publicly disclosed, and commercial launch will follow CE/FDA approval. Pre-commercial go-to-market relies on clinical trial partnerships, key opinion leader engagement (Prof. Volkmar Falk, Dr. Stephan Jacobs, Dr. Bart van Putte, Dr. Patrick Klein), and conference-driven clinical evidence dissemination (EACTS, ISCAS, ESCVS).

Cumulative funding since 2017 totals approximately €35 million-plus across seed (NextGen Ventures, Utrecht Holdings, 2017), a €10 million Series A in September 2020 led by Oost NL alongside existing backers, multiple non-dilutive grants (MIT subsidy 2018, EFRO/Horizon 2020 KARDIO project 2019, ION+ loan 2020, EIC Accelerator grant 2023), and a $25 million (approximately €22 million) Series B in April 2025 led by Bender Analytical Holding B.V. (BAH), with Invest-NL and the EIC joining existing investors. In February 2026, founder Rutger Tulleken transitioned to a Founder & Strategic Advisor role and Geert van Gansewinkel (previously CEO of GATT Technologies through its acquisition by Johnson & Johnson in 2025) was appointed CEO, signaling a pivot toward commercial-stage execution. The company has 11-50 employees and no parent or controlling entity.

Name

AMT Medical

Legal name

AMT Medical B.V.

Website

https://amt-medical.nl

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

AMT Medical B.V. is a Dutch clinical-stage medtech company developing the ELANA® Anastomotic System, a sutureless titanium clip and laser catheter platform for creating distal anastomoses in coronary artery bypass surgery. The company is pre-revenue and is pursuing CE marking in Europe and FDA approval in the United States.

Ownership category

akta.pro rank

Product category

Cardiac Surgery Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts) (HLAHAFAH)

akta.pro secondary industry

Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser) (HLAHADAC)

Keywords

• Coronary bypass devices
• Sutureless anastomosis systems
• Cardiac surgery implants
• Minimally invasive CABG
• Medical device manufacturing

Headquarters

HQ city

Utrecht

HQ country

Netherlands

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pre-Revenue Clinical Stage: The company is currently pre-revenue and clinical-stage. It has not yet obtained CE marking or FDA approval for the Elana Heart Bypass System and is conducting clinical trials (SAFE-CAB Phase I and Phase II) ahead of commercial launch. Future revenue is expected to come from sales of the medical device (single-use clip + laser catheter system) to hospitals and cardiac surgery centers.

Go-to-market motion3 records

Core offering

AMT Medical develops the ELANA Anastomotic System (also called the ELANA Heart Bypass System), a sutureless clip-and-laser surgical device that creates the distal anastomosis in coronary artery bypass grafting (CABG). The system combines a proprietary titanium clip with a laser catheter to enable standardized, reproducible anastomoses on a beating heart, supporting open, off-pump, MIDCAB, and future robotic-assisted TECAB procedures. The product is currently pre-commercial, with no CE mark or FDA approval yet, advancing through the SAFE-CAB clinical trial program.

Product overview

AMT Medical is a clinical-stage Dutch medtech company built around a single core product platform, the ELANA Anastomotic System (also referred to as the ELANA Heart Bypass System), a sutureless clip-and-laser solution for creating distal anastomoses in coronary artery bypass grafting (CABG). The system consists of two principal elements — the small titanium ELANA Clip that mechanically connects the graft to the coronary artery, and a laser catheter that creates the arteriotomy — and is designed to support both open and minimally invasive procedures (including off-pump, MIDCAB and, in the future, robotic-assisted TECAB approaches). The platform is being advanced through the SAFE-CAB clinical trial program in Europe and an Early Feasibility Trial pathway with the U.S. FDA, with the explicit goal of obtaining CE marking and eventual commercial launch; there are no separate software products, add-on modules, or acquired brands — the portfolio is a single unified surgical device platform.

Differentiator

Problem solved

Functional benefit

Brands

• ELANA® Anastomotic System: AMT Medical's flagship medical device product line: a sutureless clip-and-laser system for creating distal anastomoses in coronary artery bypass surgery. Also referenced in news as the 'ELANA Heart Bypass System' / 'ELANA Heart Bypass Solution'. ELANA is a registered trademark of AMT Medical B.V.

Products and services

• ELANA Anastomotic System (ELANA Heart Bypass System) Sutureless, clip-and-laser based surgical device designed to create the distal anastomosis in coronary artery bypass grafting (CABG). Combines a small titanium clip that connects a graft vessel to the coronary artery with a laser catheter that creates the arteriotomy, enabling standardized, reproducible anastomoses on a beating heart and supporting less invasive and robotic-assisted CABG approaches including MIDCAB and TECAB. Built on a platform originally developed for neurosurgery and redesigned by AMT Medical for cardiac application. Intended for hospitals, cardiac surgery centers, and cardiothoracic surgeons.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Getinge (Atrium / Maquet): Through its Maquet and Atrium brands, Getinge supplies cardiac surgery devices including anastomotic clips, surgical instruments, and operating-room equipment. Comparable as a broad incumbent in the cardiac surgery OR equipment and consumables space.
• LivaNova: Cardiac surgery specialist with a portfolio of CABG-related products including oxygenators, heart-lung machines, and surgical instruments. Comparable as a focused cardiac surgery incumbent whose customers (cardiac surgeons) overlap exactly with AMT's target users.
• Artivion (formerly CryoLife): Cardiac and vascular surgery company with surgical adhesives, sealants, and conduit products used in CABG. Comparable as a mid-sized cardiac surgery device specialist addressing the same procedural workflow with complementary closure and graft solutions.
• Edwards Lifesciences: Leading cardiac surgery and structural heart device company. While not directly selling a competing anastomotic product, Edwards is a relevant comparable as a high-margin cardiac surgery pure-play with a track record of acquiring enabling technologies.
• Medtronic: Global leader in cardiac surgery devices including off-pump CABG stabilizers, anastomotic aids, and CABG-focused capital equipment. Directly comparable as the dominant incumbent whose installed base AMT must displace in cardiac surgery centers.
• Corcym: Cardiac surgery device company (spun out of LivaNova/Sorin) focused on heart valve repair and replacement, aortic surgery, and CABG-related products. Comparable as a focused cardiac surgery device player serving the same cardiac surgery departments.
• Teleflex: Surgical and cardiac care device maker with a portfolio including surgical clips, closure devices, and OR consumables used in cardiac surgery. Comparable as a broad surgical device incumbent overlapping with AMT's clip-based anastomotic technology.
• Abbott: Through Guidant/Abbott Vascular legacy, Abbott commercialized the Heartstring proximal anastomotic seal device. Comparable as a large incumbent with cardiovascular surgery and structural heart franchises targeting the same surgical workflow.

Direct peers

• Terumo (Cardica / PAS-Port): Through its acquisition of Cardica, Terumo markets the PAS-Port proximal anastomotic device — the closest commercialized direct competitor to ELANA. Same procedural context (CABG anastomosis), same target customer (cardiac surgeon), and same mechanism class (connector-based).

Emerging players

• Vivasure Medical: Clinical-stage Irish medtech developing bioabsorbable vascular closure devices for large-bore percutaneous access. Comparable as a similarly sized European clinical-stage medtech pursuing a sutureless / closure paradigm in a Class III vascular indication, providing a useful comparator for late-stage clinical and regulatory execution.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/amt-medical-bv

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AMT Medical